Get started
Author

Cong Wang

ORCID: 0000-0002-6700-1775
Observed ORCID: 0000-0002-6700-1775
OpenAlex ID: A5127859576
Table S2 from Molecular and Immune Correlates of Response to First-Line De-escalated Chemotherapy plus Penpulimab and Anlotinib in Advanced Cervical Cancer
2026 · Qin Xu, Zhengrong Deng, et al.
Figure S9 from Molecular and Immune Correlates of Response to First-Line De-escalated Chemotherapy plus Penpulimab and Anlotinib in Advanced Cervical Cancer
2026 · Qin Xu, Zhengrong Deng, et al.
Table S8 from Molecular and Immune Correlates of Response to First-Line De-escalated Chemotherapy plus Penpulimab and Anlotinib in Advanced Cervical Cancer
2026 · Qin Xu, Zhengrong Deng, et al.
Table S7 from Molecular and Immune Correlates of Response to First-Line De-escalated Chemotherapy plus Penpulimab and Anlotinib in Advanced Cervical Cancer
2026 · Qin Xu, Zhengrong Deng, et al.
Table S9 from Molecular and Immune Correlates of Response to First-Line De-escalated Chemotherapy plus Penpulimab and Anlotinib in Advanced Cervical Cancer
2026 · Qin Xu, Zhengrong Deng, et al.
Table S3 from Molecular and Immune Correlates of Response to First-Line De-escalated Chemotherapy plus Penpulimab and Anlotinib in Advanced Cervical Cancer
2026 · Qin Xu, Zhengrong Deng, et al.
Table S4 from Molecular and Immune Correlates of Response to First-Line De-escalated Chemotherapy plus Penpulimab and Anlotinib in Advanced Cervical Cancer
2026 · Qin Xu, Zhengrong Deng, et al.
Figure S5 from Molecular and Immune Correlates of Response to First-Line De-escalated Chemotherapy plus Penpulimab and Anlotinib in Advanced Cervical Cancer
2026 · Qin Xu, Zhengrong Deng, et al.
Table S6 from Molecular and Immune Correlates of Response to First-Line De-escalated Chemotherapy plus Penpulimab and Anlotinib in Advanced Cervical Cancer
2026 · Qin Xu, Zhengrong Deng, et al.
Figure S12 from Molecular and Immune Correlates of Response to First-Line De-escalated Chemotherapy plus Penpulimab and Anlotinib in Advanced Cervical Cancer
2026 · Qin Xu, Zhengrong Deng, et al.
Figure S8 from Molecular and Immune Correlates of Response to First-Line De-escalated Chemotherapy plus Penpulimab and Anlotinib in Advanced Cervical Cancer
2026 · Qin Xu, Zhengrong Deng, et al.
Figure S2 from Molecular and Immune Correlates of Response to First-Line De-escalated Chemotherapy plus Penpulimab and Anlotinib in Advanced Cervical Cancer
2026 · Qin Xu, Zhengrong Deng, et al.
Table S1 from Molecular and Immune Correlates of Response to First-Line De-escalated Chemotherapy plus Penpulimab and Anlotinib in Advanced Cervical Cancer
2026 · Qin Xu, Zhengrong Deng, et al.
Figure S11 from Molecular and Immune Correlates of Response to First-Line De-escalated Chemotherapy plus Penpulimab and Anlotinib in Advanced Cervical Cancer
2026 · Qin Xu, Zhengrong Deng, et al.
Table S5 from Molecular and Immune Correlates of Response to First-Line De-escalated Chemotherapy plus Penpulimab and Anlotinib in Advanced Cervical Cancer
2026 · Qin Xu, Zhengrong Deng, et al.
Table S10 from Molecular and Immune Correlates of Response to First-Line De-escalated Chemotherapy plus Penpulimab and Anlotinib in Advanced Cervical Cancer
2026 · Qin Xu, Zhengrong Deng, et al.
Discovery of natural apigenin analogues as lysine-specific demethylase 1 inhibitors against tumoral testicular germ cells
2026 · Li-Wei Sun, Meng Zhang, et al. · Scientific Reports
PDF
Figure S4 from Molecular and Immune Correlates of Response to First-Line De-escalated Chemotherapy plus Penpulimab and Anlotinib in Advanced Cervical Cancer
2026 · Qin Xu, Zhengrong Deng, et al.
Data from Molecular and Immune Correlates of Response to First-Line De-escalated Chemotherapy plus Penpulimab and Anlotinib in Advanced Cervical Cancer
2026 · Qin Xu, Zhengrong Deng, et al.
Figure S3 from Molecular and Immune Correlates of Response to First-Line De-escalated Chemotherapy plus Penpulimab and Anlotinib in Advanced Cervical Cancer
2026 · Qin Xu, Zhengrong Deng, et al.
Figure S1 from Molecular and Immune Correlates of Response to First-Line De-escalated Chemotherapy plus Penpulimab and Anlotinib in Advanced Cervical Cancer
2026 · Qin Xu, Zhengrong Deng, et al.
Figure S10 from Molecular and Immune Correlates of Response to First-Line De-escalated Chemotherapy plus Penpulimab and Anlotinib in Advanced Cervical Cancer
2026 · Qin Xu, Zhengrong Deng, et al.
Figure S7 from Molecular and Immune Correlates of Response to First-Line De-escalated Chemotherapy plus Penpulimab and Anlotinib in Advanced Cervical Cancer
2026 · Qin Xu, Zhengrong Deng, et al.
Figure S6 from Molecular and Immune Correlates of Response to First-Line De-escalated Chemotherapy plus Penpulimab and Anlotinib in Advanced Cervical Cancer
2026 · Qin Xu, Zhengrong Deng, et al.
Works count: 24
Citation count:
H-index:
I10-index:
Year
Topic
Type